Innate Pharma (IPHA) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases.
The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma.
Additionally, Innate said it is advancing its Antibody-Drug Conjugate programs, with lead candidate IPH4502 in a phase 1 trial for advanced solid tumors.
Innate is also seeking a partner for lacutamab in T-cell lymphomas and collaborating with AstraZeneca (AZN) on monalizumab, which is in a phase 3 trial for non-small cell lung cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。